CASSAVA SCIENCES INC
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
FLNA$0.48-2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(In thousands)
| Years ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Cash flows from operating activities: | |||
| Net loss | $(97,217) | $(76,246) | $(32,385) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Stock-based compensation | 4,586 | 2,066 | 1,759 |
| Depreciation | 1,084 | 804 | 310 |
| Amortization of intangible assets | 446 | 497 | 224 |
| Changes in operating assets and liabilities: | |||
| Prepaid and other assets | 1,714 | 1,189 | (10,956) |
| Operating lease right-of-use assets and liabilities | (17) | (9) | 28 |
| Accounts payable and other accrued expenses | 6,896 | (3,449) | 6,215 |
| Accrued development expense | 757 | (523) | 2,084 |
| Accrued compensation and benefits | 30 | (1,707) | 1,794 |
| Other liabilities | (304) | (136) | 731 |
| Net cash used in operating activities | (82,025) | (77,514) | (30,196) |
| Cash flows from investing activities: | |||
| Purchase of property and equipment | (414) | (2,712) | (22,214) |
| Net cash used in investing activities | (414) | (2,712) | (22,214) |
| Cash flows from financing activities: | |||
| Proceeds from issuance of common stock upon exercise of stock options | 2,560 | 475 | 1,824 |
| Proceeds from issuance of common stock upon exercise of 2018 warrants | — | — | 692 |
| Proceeds from common stock offering, net of issuance costs | — | 47,329 | 189,825 |
| Net cash provided by financing activities | 2,560 | 47,804 | 192,341 |
| Net (decrease) increase in cash and cash equivalents | (79,879) | (32,422) | 139,931 |
| Cash and cash equivalents at beginning of period | 201,015 | 233,437 | 93,506 |
| Cash and cash equivalents at end of period | $121,136 | $201,015 | $233,437 |
| Supplemental cash flow information: | |||
| Non-cash investing activities | |||
| Purchases of property and equipment included in accounts payable | $— | $340 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.